CONMED Corp (CNMD)

Quarterly Report Filed: 2026-04-30

Key Insights

CONMED operates through two primary business segments (Orthopedic Surgery and General Surgery) with geographic diversification across US, EMEA, Asia Pacific, and Americas ex-US, providing revenue stability across multiple markets and customer bases.
The company generates revenue through both point-in-time and over-time revenue recognition methods, indicating a mix of product sales and service/contract arrangements typical of medical device manufacturers.
Treasury stock activity and accumulated other comprehensive income adjustments suggest active capital management and exposure to foreign exchange hedging, reflecting international operations and potential currency headwinds.
Q1 2026 filing structure mirrors comparative Q1 2025 data, enabling year-over-year performance analysis across segments, though specific revenue and profit figures are not visible in the provided metadata.

Current Report Filed: 2026-04-29

Key Insights

CONMED released Q1 2026 earnings results on April 29, 2026, indicating routine quarterly financial reporting with no material transactions, acquisitions, or leadership changes disclosed.
Andrew Moller is identified as Interim Principal Financial Officer and VP, Corporate Controller, suggesting a potential temporary CFO arrangement that warrants monitoring for permanent appointment announcements.
The 8-K filing contains minimal disclosure beyond earnings announcement, with actual financial results relegated to the press release exhibit, indicating this is a standard quarterly earnings report without material events.

Insider Trading Filed: 2026-04-02

Key Insights

The CEO received a $1M equity award in the form of restricted stock units (RSUs) that will vest over 3 years with a 2-year post-vest holding period.
The CEO's increased stake in the company through this RSU grant aligns his interests with those of shareholders.
The timing of the award, just before the end of the fiscal year, suggests the company may be rewarding the CEO for strong performance.

Current Report Filed: 2026-03-13

Key Insights

CONMED Corporation appointed Andrew Moller as Interim Principal Financial Officer, effective March 15, 2026. Moller has extensive financial leadership experience at Smith & Nephew and Stanley Black & Decker.
There were no changes to Moller's compensation arrangements in connection with his appointment as Interim Principal Financial Officer.
There are no related-party transactions or family relationships between Moller and the members of CONMED's Board of Directors that require disclosure.

Insider Trading Filed: 2026-03-04

Key Insights

Brent Lalomia, the Executive VP RA, QA of CONMED Corporation, acquired 9,554 restricted stock units (RSUs) and 11,322 stock options on March 2, 2026, indicating the company's commitment to incentivizing its key executive team.
The RSUs and options granted to Lalomia have a 10-year expiration period, suggesting a long-term alignment between the executive's interests and those of CONMED's shareholders.
The granted RSUs and options are subject to vesting schedules, which could provide an incentive for Lalomia to focus on CONMED's long-term performance and growth.

Insider Trading Filed: 2026-03-04

Key Insights

Matthew Schabacker, VP GM of Advanced Surgical at CONMED Corporation, acquired 9,827 restricted stock units (RSUs) and 11,646 stock options on March 2, 2026, indicating his confidence in the company's future performance.
The RSUs and stock options granted to Schabacker are subject to vesting schedules, aligning his interests with long-term shareholder value creation.
Insider transactions, such as this acquisition of equity-based awards, can provide insights into management's views on the company's prospects and growth potential.

Insider Trading Filed: 2026-03-04

Key Insights

John D. Ferrell, the Executive Vice President of HR at CONMED Corporation, has been granted 9,282 restricted stock units (RSUs) and 10,999 stock options, which will vest over a multi-year period, indicating the company's commitment to incentivizing and retaining its key executive talent.
The granted RSUs and stock options have an expiration date of March 2, 2036, providing Ferrell with long-term alignment with CONMED's performance and shareholder value creation.
This insider transaction suggests CONMED's leadership believes in the company's future prospects and is willing to invest their own compensation in the form of equity awards.

Insider Trading Filed: 2026-03-04

Key Insights

Johonna Marie Pelletier, the Treasurer and VP of Tax at CONMED Corp, has been granted 5,896 restricted stock units (RSUs) that will vest over a three-year period.
The RSU grant is part of the company's 2025 Long-Term Incentive Plan, which aligns the executive's interests with those of the shareholders.
This insider grant of equity-based compensation suggests Pelletier's commitment to CONMED's long-term growth and performance.

Insider Trading Filed: 2026-03-04

Key Insights

Peter K. Shagory, the EVP of Strategy and Corporate Development at CONMED Corp, acquired 9,282 restricted stock units (RSUs) and 10,999 stock options on March 2, 2026, indicating his commitment to the company's long-term success.
The RSUs and stock options are subject to vesting schedules, aligning Shagory's interests with those of CONMED's shareholders.
Insider transactions like this can provide insights into management's confidence in the company's future prospects and their alignment with shareholder value creation.

Insider Trading Filed: 2026-03-04

Key Insights

Hollie K. Foust, the General Counsel and Corporate Secretary of CONMED Corporation, acquired 10,919 restricted stock units (RSUs) and 12,940 stock options on March 2, 2026, indicating insider confidence in the company's future performance.
The RSUs and stock options have vesting periods of 3 years and 4 years respectively, suggesting a long-term commitment from the reporting person.
The transaction increases Foust's beneficial ownership of CONMED securities, potentially aligning her interests with those of shareholders.

Insider Trading Filed: 2026-03-04

Key Insights

The reporting person, Andrew James Moller, has been granted 5,896 restricted stock units (RSUs) of CONMED Corporation, which will vest over a 3-year period.
The RSUs were granted on March 2, 2026 and will expire on March 2, 2036, indicating a long-term incentive for the reporting person.
The reporting person currently holds 5,896 RSUs, which represents their direct ownership in CONMED Corporation's common stock.

Insider Trading Filed: 2026-03-04

Key Insights

The CEO of CONMED Corporation, Pat Beyer, has been granted 28,800 restricted stock units (RSUs) and 68,258 stock options, indicating confidence in the company's long-term growth prospects.
The RSUs and stock options have a 10-year vesting period, aligning the CEO's incentives with long-term shareholder value creation.
The timing of this equity award, granted in March 2026, suggests the company may be preparing for a new strategic initiative or growth phase.

Insider Trading Filed: 2026-02-26

Key Insights

Mark Kaye, a director at CONMED Corp, exercised 152 restricted stock units (RSUs) on 02/24/2026, indicating his continued ownership and commitment to the company.
The vesting of the RSUs aligns Kaye's interests with shareholders, as the RSUs represent a contingent right to receive CONMED common stock.
This transaction represents a routine insider event and does not signal any significant changes to Kaye's overall ownership or the company's outlook.

Annual Report Filed: 2026-02-17

Key Insights

CONMED's revenue and profitability appear to be growing steadily over the past few years, with net sales increasing by over 10% and gross margins remaining stable.
The company's balance sheet appears healthy, with a manageable level of debt and sufficient liquidity to fund operations and growth initiatives.
CONMED has been actively investing in research and development, as well as expanding its product portfolio through acquisitions, which could support future growth opportunities.

Current Report Filed: 2026-01-28

Key Insights

CONMED Corporation reported fourth quarter 2025 financial results, indicating the company's performance for the full year.
The company did not provide any forward-looking guidance or commentary on the current business environment in the press release.
Without additional details on the company's financial performance or strategic initiatives, there are limited insights that can be gleaned from this routine earnings release.

Current Report Filed: 2026-01-12

Key Insights

CONMED Corporation provided preliminary financial guidance for 2026, indicating potential growth and performance for the upcoming year.
The company plans to present the investor presentation at the upcoming J.P. Morgan Healthcare Conference, which could signal important strategic updates or developments for investors to consider.
The filing does not mention any material agreements, leadership changes, or earnings surprises, suggesting a routine update rather than a significant event.

Current Report Filed: 2026-01-08

Key Insights

CONMED Corporation announced the separation of its Chief Financial Officer, Todd Garner, effective March 15, 2026 or the date a new CFO is appointed.
The company has retained an executive search firm to find a permanent replacement for the CFO role, indicating a planned leadership transition.
During the transition period, Garner will continue to receive his current compensation and benefits, and his outstanding equity awards will continue to vest through November 2026.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information